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18 This guidance provides assistance to sponsors of investigational new drug applications (INDs), 19 new drug applications (NDAs), abbreviated new drug applications (ANDAs), biologic license applications (BLAs), and supplements in developing bioanalytical method validation information 21 used in human clinical pharmacology, bioavailability (BA), and bioequivalence (BE) studies that 22 require pharmacokinetic (PK) or biomarker concentration evaluation. This guidance also applies 23 to bioanalytical methods used for nonclinical pharmacology/toxicology studies. For studies 24 related to the veterinary drug approval process (Investigational New Animal Drug Applications (INADs), New Animal Drug Applications (NADAs), and Abbreviated New Animal Drug 26 Applications (ANADAs)), this guidance may apply to blood and urine BA, BE, and PK studies. 27 28 The information in this guidance generally applies to bioanalytical procedures, such as gas 29 chromatography (GC); high-pressure liquid chromatography (LC); combined GC and LC mass spectrometric (MS) procedures, such as LC-MS, LC-MS-MS, GC-MS, and GC-MS-MS; and 31 ligand binding assays (LBAs), and immunological and microbiological procedures that are 32 performed for the quantitative determination of drugs and/or metabolites, and therapeutic 33 proteins in biological matrices, such as blood, serum, plasma, urine, tissue, and skin. 34 This guidance provides general recommendations for bioanalytical method validation. The 36 recommendations can be modified depending on the specific type of analytical method used. 37 38 Originally issued in 2001, this guidance has been revised to reflect advances in science and 39 technology related to validating bioanalytical methods. The guidance is being reissued in draft to enable public review and comment before it is finalized. 41 42 FDA's guidance documents, including this guidance, do not establish legally enforceable 43 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should 44 be viewed only as recommendations, unless specific regulatory or statutory requirements are 45 cited. The use of the word should in Agency guidances means that something is suggested or 46 recommended, but not required. 47 48 II. BACKGROUND 49 50 This guidance was originally developed based on the deliberations following two workshops: 51 Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies 52 (December 3-5, 1990 2 ) and Bioanalytical Methods Validation: A Revisit With a Decade of 53 Progress (January 12-14, 2000 3 ). Since publication of the guidance in May 2001, additional 54 workshops have been held that have helped guide the current revisions to the guidance: the 55 Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for 56 Chromatographic and Ligand Binding Assays (May 1-3, 2006 4 ) and the AAPS/FDA Workshop 57 on Incurred Sample Reanalysis (February 2008 5 ). 58 59 Selective, sensitive, and validated analytical methods for the quantitative evaluation of drugs and 60 their metabolites (analytes) and biomarkers are critical for the successful conduct of nonclinical 61 and/or biopharmaceutics and clinical pharmacology studies. Validating bioanalytical methods 62 includes performing all of the procedures that demonstrate that a particular method used for 63 quantitative measurement of analytes in a given biological matrix (e.g., blood, plasma, serum, or 64 urine) is reliable and reproducible for the intended use. Fundamental parameters for this 65 73 Validation involves documenting, through the use of specific laboratory investigations, that the 74 performance characteristics of a method are suitable and reliable for the intended analytical 75 applications. The acceptability of analytical data corresponds directly to the criteria used to 76 validate the method. For pivotal studies that require regulatory action for approval or labeling, 77 such as BE or PK studies, the bioanalytical methods should be fully validated. For exploratory 78 methods used for the sponsor's internal decision making, less validation may be sufficient. 79 80 When changes are made to a previously validated method, additional validation may be needed. 81 For example, published methods of analysis are often modified to suit the requirements of the 82 laboratory performing the assay, and during the course of a typical drug development program, a 83 defined bioanalytical method often undergoes many modifications. These modifications should 84 be validated to ensure suitable performance of the analytical method. The evolutionary changes 85 needed to support specific studies call for different levels of validation to demonstrate the 86 validity of method performance. 87 88 The following define and characterize the different types and levels of methods validation. 89 119 Cross-validation is a comparison of validation parameters when two or more bioanalytical 120 methods are used to generate data within the same study or across different studies. An example 121 of cross-validation would be a situation in which an original validated bioanalytical method 122 serves as the reference, and the revised bioanalytical method is the comparator. The 123 comparisons should be done both ways. 124 125 When sample analyses within a single study are conducted at more than one site or more than 126 one laboratory, cross-validation with spiked matrix standards and subject samples should be 127 conducted at each site or laboratory to establish inter-laboratory reliability. Cross-validation 128 should also be considered when data generated using different analytical techniques (e.g., LC 129 MS/MS vs. ELISA 6 ) in different studies are included in a regulatory submission. All 130 modifications to an existing method should be assessed to determine the recommended degree of 131 validation. 132 133 134
The analytical laboratory conducting nonclinical pharmacology/toxicology studies for regulatory submissions should adhere to FDA's Good Laboratory Practices (GLPs) requirements 7 (21 CFR 135 Part 58). The bioanalytical method for human BA, BE, PK, and drug interaction studies must 136 meet the criteria specified in 21 CFR 320.29. 137 138 Analytical laboratories should have written standard operating procedures (SOPs) to ensure a 139 complete system of quality control and assurance. SOPs should cover all aspects of analysis 140 from the time the sample is collected and reaches the laboratory until the results of the analysis 141 are reported. The SOPs also should include record keeping, security and chain of sample custody 142 (accountability systems that ensure integrity of test articles), sample preparation, and analytical 143 tools such as methods, reagents, equipment, instrumentation, and procedures for quality control 144 and verification of results. 145 146 The following sections discuss in more detail chromatographic methods, ligand binding assays, 147 incurred sample reanalysis, and other issues that should be considered and how best to document 148 validation methods. 149 150 III. CHROMATOGRAPHIC METHODS 151 152 A.
Reference Standards 153 154 Analysis of drugs and their metabolites in a biological matrix is performed using calibration 155 standards and quality control samples (QCs) spiked with reference standards. The purity of the 156 reference standard used to prepare spiked samples can affect study data. For this reason, 157 authenticated analytical reference standards of known identity and purity should be used to 158 prepare solutions of known concentrations. If possible, the reference standard should be identical 159 to the analyte. When this is not possible, an established chemical form (free base or acid, salt or 160 ester) of known purity can be used. 161 162 Three types of reference standards are usually used: (1) certified reference standards (e.g., USP 163 compendial standards), (2) commercially-supplied reference standards obtained from a reputable 164 commercial source, and/or (3) other materials of documented purity custom-synthesized by an 165 analytical laboratory or other noncommercial establishment. The source and lot number, 166 expiration date, certificates of analyses when available, and/or internally or externally generated 167 evidence of identity and purity should be furnished for each reference and internal standard (IS) 168 used. If the reference or internal standard expires, stock solutions made with this lot of standard 169 should not be used unless purity is re-established. 170 171 B.
Bioanalytical Method Development and Validation 172 6 Enzyme linked immunosorbent assay. 7 For the CVM, all bioequivalence studies are subject to Good Laboratory Practices. 173 A specific, detailed, written description of the bioanalytical method should be established a 174 priori. This can be in the form of a protocol, study plan, report, and/or SOP. Each step in the 175 method should be investigated to determine the extent to which environmental, matrix, or 176 procedural variables could affect the estimation of analyte in the matrix from the time of 177 collection of the samples to the time of analysis. 178 179 Appropriate steps should be taken to ensure the lack of matrix effects throughout the application 180 of the method, especially if the matrix used for production batches is different from the matrix 181 used during method validation. Matrix effects on ion suppression or enhancement or on 182 extraction efficiency should be addressed. A bioanalytical method should be validated for the 183 intended use or application. All experiments used to make claims or draw conclusions about the 184 validity of the method should be presented in a report (method validation report), including a 185 description of validation runs that failed. 186 187 Measurements for each analyte in the biological matrix should be validated. Method 188 development and validation for a bioanalytical method should include demonstrations of (1) 189 selectivity; (2) accuracy, precision, and recovery; (3) the calibration curve; (4) sensitivity; (5) 190 reproducibility; and (6) stability of analyte in spiked samples. 191 192
1. Selectivity 193 194 Selectivity is the ability of an analytical method to differentiate and quantify the analyte in the 195 presence of other components in the sample. Evidence should be provided that the substance 196 quantified is the intended analyte. Analyses of blank samples of the appropriate biological 197 matrix (plasma, urine, or other matrix) should be obtained from at least six sources. Each blank 198 sample should be tested for interference, and selectivity should be ensured at the lower limit of 199 quantification (LLOQ). 200 201 Potential interfering substances in a biological matrix include endogenous matrix components; 202 metabolites; decomposition products; and, in the actual study, concomitant medication and other 203 xenobiotics. If the method is intended to quantify more than one analyte, each analyte should be 204 tested to ensure that there is no interference. 205 206 2. Accuracy, Precision, and Recovery 207 208 The accuracy of an analytical method describes the closeness of mean test results obtained by 209 the method to the actual value (concentration) of the analyte. Accuracy is determined by 210 replicate analysis of samples containing known amounts of the analyte (i.e., QCs). Accuracy 211 should be measured using a minimum of five determinations per concentration. A minimum of 212 three concentrations in the range of expected study sample concentrations is recommended. The 213 mean value should be within 15% of the nominal value except at LLOQ, where it should not 214 deviate by more than 20%. The deviation of the mean from the nominal value serves as the 215 measure of accuracy. 216 217 The precision of an analytical method describes the closeness of individual measures of an 218 analyte when the procedure is applied repeatedly to multiple aliquots of a single homogeneous 219 volume of biological matrix. Precision should be measured using a minimum of five 220 determinations per concentration. A minimum of three concentrations in the range of expected 221 study sample concentrations is recommended. The precision determined at each concentration 222 level should not exceed 15% of the coefficient of variation (CV) except for the LLOQ, where it 223 should not exceed 20% of the CV. Precision is further subdivided into within-run and between-224 run precision. Within-run precision (intra-batch precision or within-run repeatability) is an 225 assessment of precision during a single analytical run. Between-run precision (inter-batch 226 precision or between-run repeatability) is an assessment of precision over time and may involve 227 different analysts, equipment, reagents, and laboratories. 228 229 Sample concentrations above the upper limit of the standard curve should be diluted. The 230 accuracy and precision of these diluted samples should be demonstrated in the method 231 validation. 232 233 The recovery of an analyte in an assay is the detector response obtained from an amount of the 234 analyte added to and extracted from the biological matrix, compared to the detector response 235 obtained for the true concentration of the analyte in solvent. Recovery pertains to the extraction 236 efficiency of an analytical method within the limits of variability. Recovery of the analyte need 237 not be 100%, but the extent of recovery of an analyte and of the internal standard should be 238 consistent, precise, and reproducible. Recovery experiments should be performed by comparing 239 the analytical results for extracted samples at three concentrations (low, medium, and high) with 240 unextracted standards that represent 100% recovery. 241 242
3. Calibration Curve 243 244 A calibration (standard) curve is the relationship between instrument response and known 245 concentrations of the analyte. The relationship between response and concentration should be 246 continuous and reproducible. A calibration curve should be generated for each analyte in the 247 sample. The calibration standards can contain more than one analyte. A calibration curve should 248 be prepared in the same biological matrix as the samples in the intended study by spiking the 249 matrix with known concentrations of the analyte. In rare cases, matrices may be difficult to 250 obtain (e.g., cerebrospinal fluid). In such cases, calibration curves constructed in surrogate 251 matrices should be justified. Concentrations of standards should be chosen on the basis of the 252 concentration range expected in a particular study. A calibration curve should consist of a blank 253 sample (matrix sample processed without analyte or internal standard), a zero sample (matrix 254 sample processed without analyte but with internal standard), and at least six non-zero samples 255 (matrix samples processed with analyte and internal standard) covering the expected range, 256 The chemical stability of an analyte in a given matrix under specific conditions for given time 336 intervals is assessed in several ways. Pre-study stability evaluations should cover the expected 337 sample handling and storage conditions during the conduct of the study, including conditions at 338 the clinical site, during shipment, and at all other secondary sites. 339 340 Drug stability in a biological fluid is a function of the storage conditions, the physicochemical 341 properties of the drug, the matrix, and the container system. The stability of an analyte in a 342 particular matrix and container system is relevant only to that matrix and container system and 343 should not be extrapolated to other matrices and container systems. 344 345 Stability testing should evaluate the stability of the analytes during sample collection and 346 handling, after long-term (frozen at the intended storage temperature) and short-term (bench top, 347 room temperature) storage, and after freeze and thaw cycles and the analytical process. Bioanalytical Method Development and Validation 492 493 A specific, detailed, written description of the bioanalytical method should be established a 494 priori. This can be in the form of a protocol, study plan, report, and/or SOP. Each step in the 495 method should be investigated to determine the extent to which environmental, matrix, or 496 procedural variables can affect the estimation of analyte in the matrix from the time of collection 497 of the samples to the time of analysis. 498 499 It may be important to consider the variability of the matrix. Appropriate steps should be taken to 500 ensure the lack of matrix effects throughout the application of the method, especially if the 501 nature of the matrix changes from the matrix used during method validation. A bioanalytical 502 method should be validated for the intended use or application. All experiments used to make 503 claims or draw conclusions about the validity of the method should be presented in a report 504 (method validation report). 505 506 Measurements for each analyte in the biological matrix should be validated. Method 507 development and validation for a bioanalytical method should include demonstrations of (1) 508 selectivity, (2) accuracy, precision, recovery, (3) the calibration curve, (4) sensitivity, (5) 509 reproducibility, and (6) stability of analyte in spiked samples. 510 511
1. Selectivity 512 513 As with chromatographic methods (described in Section III), LBAs should be shown to be 514 selective for the analyte. 2. Accuracy, Precision and Recovery 537 538 Accuracy is determined by replicate analysis of samples containing known amounts of the 539 analyte (QCs). Accuracy should be measured using a minimum of five determinations per 540 concentration. A minimum of three concentrations in the range of expected study sample 541 concentrations is recommended. The mean value should be within 20% of the actual value 542 except at LLOQ, where it should not deviate by more than 25%. 543 544 The precision should be measured using a minimum of five determinations per concentration. A 545 minimum of three concentrations in the range of expected study sample concentrations is 546 recommended. The precision determined at each concentration level should not exceed 20% of 547 the CV except for the LLOQ, where it should not exceed 25% of the CV. Precision is further 548 subdivided into within-run and between-run precision. Within-run (also known as intra-batch 549 precision or repeatability) is an assessment of the precision during a single analytical run. 550 Between-run precision (also known as interbatch precision or repeatability), is a measurement of 551 the precision with time, and may involve different analysts, equipment, reagents, and 552 laboratories. 553 554 Samples with concentrations over the ULOQ should be diluted with the same matrix as used for 555 the study samples, and accuracy and precision should be demonstrated. 556 557 For LBAs that employ sample extraction, the recovery of an analyte is the measured 558 concentration relative to the known amount added to the matrix. Recovery experiments should be 559 performed for extracted samples at three concentrations. 560 561
3. Calibration Curve 562 563 Most LBA calibration (standard) curves are inherently nonlinear and, in general, more 564 concentration points may be recommended to define the fit over the standard curve range than 565 for chromatographic assays. In addition to their nonlinear characteristics, the response-error 566 relationship for immunoassay standard curves is a variable function of the mean response 567 (heteroscedasticity). For these reasons, the standard curve should consist of a minimum of six, 568 duplicate non-zero calibrator concentrations covering the entire range including LLOQ and 569 excluding blanks (either single or replicate). The concentration-response relationship is most 570 often fitted to a 4-or 5-parameter logistic model, although other models may be used with 571 suitable validation. Calibrators should be prepared in the same matrix as the study samples. data for the repeat analysis and reporting should be clearly documented.
740
 Samples involving multiple analytes should not be rejected based on the data from one 741 analyte failing the acceptance criteria.
742
 The data from rejected runs should be documented, but need not be reported; however, 743 the fact that a run was rejected and the reason for failure should be reported.
744
 If a unique or disproportionately high concentration of a metabolite is discovered in 745 human studies, a fully validated assay may need to be developed for the metabolite 746 depending on its activity (see guidance for industry Safety Testing of Drug Metabolites).
747
 Reported method validation data and the determination of accuracy and precision should 748 include all outliers; however, calculations of accuracy and precision, excluding values 749 that are determined as outliers, should also be reported.
750 V. INCURRED SAMPLE REANALYSIS 751 752 Incurred sample reanalysis (ISR) is a necessary component of bioanalytical method validation 753 and is intended to verify the reliability of the reported subject sample analyte concentrations. 754 ISR is conducted by repeating the analysis of a subset of subject samples from a given study in 755 separate runs on different days to critically support the precision and accuracy measurements 756 established with spiked QCs; the original and repeat analysis is conducted using the same 757 bioanalytical method procedures. ISR samples should be compared to freshly prepared 758 calibrators. ISR is expected for all in vivo human BE studies and all pivotal PK or 759 pharmacodynamic (PD) studies. For nonclinical safety studies, the performing laboratory should 760 conduct ISR at least once for each method and species. 761 762 For regulatory submissions containing only a few studies, it may be advantageous to incorporate 763 ISR into the method development and validation stage by conducting a pilot study prior to the 764 pivotal study. This approach allows for the remediation of methodological issues prior to 765 conduct of the pivotal study. For applications with a greater number of pivotal PK or PD studies, 766 ISR should be monitored in a larger number and variety of studies. 767 768 Standard operating procedures should be established and followed to address the following 769 points: 770 771
 The total number of ISR samples should be 7% of the study sample size. The recommendations in this guidance pertain only to the validation of assays to measure in vivo 814 biomarker concentrations in biological matrices such as blood or urine. Considerable effort also 815 goes into defining the biological function of biomarkers, and confusion may arise regarding 816 terminology. Information about defining the biological role of a biomarker is available on the 817 FDA Drug Development Tools website. 818 819 Biomarkers are increasingly used to assess the effects of new drugs and therapeutic biological 820 products in patient populations. Because of the important roles biomarkers can play in 821 evaluating the safety and/or effectiveness of a new medical product, it is critical to ensure the 822 integrity of the data generated by assays used to measure them. Biomarkers can be used for a 823 wide variety of purposes during drug development; therefore, a fit-for-purpose approach should 824 be used when evaluating the extent of method validation that is appropriate. When biomarker 825 data will be used to support a regulatory action, such as the pivotal determination of safety 826 and/or effectiveness or to support labeled dosing instructions, the assay should be fully validated. 827 828 For assays intended to support early drug development (e.g., candidate selection, go-no-go 829 decisions, proof-of-concept), the sponsor should incorporate the extent of method validation they 830 deem appropriate. 831 832 Method validation for biomarker assays should address the same questions as method validation 833 for PK assays. The accuracy, precision, selectivity, range, reproducibility, and stability of a 834 biomarker assay are important characteristics that define the method. The approach used for PK 835 assays should be the starting point for validation of biomarker assays, although FDA realizes that 836 some characteristics may not apply or that different considerations may need to be addressed. 837 838 C.
Diagnostic Kits 839 840 Diagnostic kits are sometimes co-developed with new drug or therapeutic biologic products. The 841 recommendations in this section of the guidance do not apply to commercial diagnostic kits that 842 are intended for point-of-care patient diagnosis, but rather to analytical methods that are used 843 during the development of new drugs and therapeutic biologics. The reader should refer to the 844 appropriate CDRH guidance documents regarding FDA expectations for commercial diagnostic 845 kits. Furthermore, these recommendations do not apply to Clinical Laboratory Improvements 846 Amendments (CLIA)-regulated entities or to assays designed to quantify or identify genes or 847 genetic polymorphisms. 848 849 If a sponsor uses a commercially available diagnostic kit to measure a biomarker, drug, or 850 therapeutic biologic concentration during the development of a novel drug or therapeutic 851 biologic product, FDA makes the following recommendations. 852 853 Ligand binding assay (LBA) kits with various detection platforms are sometimes used to 854 determine analyte concentrations in PK or PD studies when the reported results must exhibit 855 sufficient precision and accuracy. Because such kits are generally developed for use as clinical 856 diagnostic tools, their suitability for use in PK or PD studies should be demonstrated. 857 858 Diagnostic kit validation data provided by the manufacturer may not ensure reliability of the kit 859 method for drug development purposes. 
912
 Bioanalytical reports of the application of any methods to study sample analysis.
913
 Overall summary information including limitations to use. 914 All relevant documentation necessary for reconstructing the study as it was conducted and 915 reported should be maintained in a secure environment. Relevant documentation includes, but is 916 not limited to, source data; protocols and reports; records supporting procedural, operational, and 917 environmental concerns; and correspondence records between the involved parties. 918 919 Regardless of the documentation format (i.e., paper or electronic), records should be 920 contemporaneous with the event, and subsequent alterations should not obscure the original data. 921 The basis for changing or reprocessing data should be documented with sufficient detail, and the 922 original record should be maintained. Electronic audit trails should be available for all 923 chromatography acquisition and data processing software and other means of electronic data 924 capture. Information related to each bioanalytical run should be maintained at the laboratory and 925 should include the analysts performing the run, start and stop times (duration), raw data, 926 integration codes, and/or other reporting codes. 927 928 A.
System Suitability/Equilibration 929 930 System suitability is routinely assessed before an analytical run. Data generated from system 931 suitability checks should be maintained in a specific file on-site and should be available for 932 inspection. System suitability samples should be different from the study samples, standards, and 933 QCs to be analyzed in the run. Therefore, study samples, standards, or QCs should not be used 934 as their own system suitability samples within the analytical run. 935 936 B.
Summary Information 937 938 Summary information should include: 939  940  summary of assay methods used for each study protocol. Each summary should 941 provide the protocol number, protocol title, assay type, assay method identification code, 942 bioanalytical report code, and effective date of the method.
943
 For each analyte, a summary table of all the relevant method validation reports should be 944 provided including partial validation, and cross-validation reports. The table should  945 include assay method identification code, type of assay, the reason for the new method or 946 additional validation (e.g., to lower the limit of quantification), and the dates of final 947
reports. Changes made to the method should be clearly identified.
948
 A summary table cross-referencing multiple identification codes should be provided 949
when an assay has different codes for the assay method, validation reports, and 950 bioanalytical reports. 
956
 An operational description of the analytical method used in the study.
957
 detailed description of the assay procedure (analyte, IS, sample pre-treatment, method 958 of extraction, and analysis). 
